IL-STATS-PERFORM
7.10.2019 13:02:09 CEST | Business Wire | Press release
Today, Stats Perform , the revolutionary leader in sports AI and data, and Control Risks , the leading specialist risk consultancy, announce a unique partnership to bring best-in-class comprehensive sports integrity solutions to the market.
Through Stats Perform’s Integrity Unit, sports industry stakeholders such as rights holders, International Federations and Governing Bodies will be able to access Control Risks’ global investigative capabilities to help drive out corruption and match-fixing. Integrity units and compliance departments will have access to a full range of solutions, including forensic accounting, data analytics and traditional investigative capabilities, to manage risk or conduct investigations.
The partnership will combine Stats Perform’s offering across prevention, detection and investigation with Control Risks’ global investigative practice and experience in building resilient and compliant governance programmes. Together, they will help stakeholders ensure their integrity, anti-doping and compliance programmes are fit-for-purpose, while protecting the long-term value of their brands.
Furthermore, global sport stakeholders will be able to utilise the full suite of services the partnership has to offer, whether it is a team requiring due diligence on a potential investor, sponsor or new signing, or a business looking to partner with a new league or competition. The partnership will enable sports stakeholders to manage both sporting integrity and business risks in one place.
Nick Allan , CEO of Control Risks, said: “We are delighted to announce this exciting new partnership with Stats Perform to help the sports industry in its desire to combat the threats to its integrity posed by corruption and match-fixing. Our global investigations capabilities will enable all stakeholders, to be able to call on our support as part of their contract with Stats Perform.”
Mike Perez , COO of Stats Perform, said: “As the sports industry goes through a data revolution, our existing integrity services will benefit from complementary investigative capabilities to identify, investigate and respond to threats. We are very pleased to move forward with Control Risks who have the global capabilities to match our aspirations.”
Jonny Gray , Global Head of Sport at Control Risks, said: “This is a very exciting development as the sports industry looks for comprehensive support to combat existential threats to its integrity, trust and value. It gives Stats Perform’s clients the opportunity for a complete integrity solution.”
Jake Marsh , Head of Integrity at Stats Perform, said: “Sports stakeholders face a variety of governance and integrity challenges. Our role is not simply to help them identify and mitigate risk, but to assist in investigation and response. Our partnership with Control Risks helps us do that and provide a better, more complete service to our clients.”
About Control Risks
Control Risks is a specialist risk consulting firm that helps create secure, compliant and resilient organizations. We believe that taking risks is essential to success, so we provide the insight and intelligence you need to realize opportunities and grow.
Our experts across 34 offices bring experience in prosecution and law enforcement, accounting, management consulting, regional business intelligence, forensic technology and cyber security to advise the world’s largest multinational companies on major regulatory issues, conduct complex cross-border investigations and build robust compliance programs.
Learn more at www.controlrisk.com/sport
About Stats Perform
Stats Perform collects the richest sports data in the world and transforms it through revolutionary artificial intelligence (AI) to unlock the most in-depth insights for media and technology, betting and team performance. With company roots dating back almost 40 years, Stats Perform embraces and solves the dynamic nature of sport – be that for digital and broadcast media with differentiated storytelling, tech companies with reliable and fast data to power their innovations, sportsbooks with in-play betting and integrity services, or teams with first-of-its-kind AI analysis software. As the leading sports data and AI company, Stats Perform works with the top global sports media, tech companies, sportsbooks, teams and leagues.
For more information, visit StatsPerform.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005277/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom